# Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy

> **NCT04605146** · NA · RECRUITING · sponsor: **Hospices Civils de Lyon** · enrollment: 100 (estimated)

## Conditions studied

- Melanoma
- Lung Cancer
- Renal Cancer

## Interventions

- **BEHAVIORAL:** Tele-monitoring

## Key facts

- **NCT ID:** NCT04605146
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-05
- **Primary completion:** 2028-11-05
- **Final completion:** 2028-11-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04605146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04605146, "Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04605146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*